Multicenter, randomized phase II trial of bevacizumab plus folinic acid, fluorouracil, gemcitabine (FFG) versus bevacizumab plus folinic acid, fluorouracil, oxaliplatin (FOLFOX4) as first-line therapy for patients with advanced colorectal cancer.
about
Effectiveness and safety of monoclonal antibodies for metastatic colorectal cancer treatment: systematic review and meta-analysisEstablishment, characterization and chemosensitivity of three mismatch repair deficient cell lines from sporadic and inherited colorectal carcinomasPrechemotherapy Touch Sensation Deficits Predict Oxaliplatin-Induced Neuropathy in Patients with Colorectal Cancer.Establishment of a predictive genetic model for estimating chemotherapy sensitivity of colorectal cancer with synchronous liver metastasisRole of bevacizumab in colorectal cancer growth and its adverse effects: a review.In vitro and in vivo studies of pharmacokinetics and antitumor efficacy of D07001-F4, an oral gemcitabine formulation.Thromboembolic Events Associated with Bevacizumab plus Chemotherapy for Patients with Colorectal Cancer: A Meta-Analysis of Randomized Controlled Trials.A network meta-analysis on the efficacy of sixteen targeted drugs in combination with chemotherapy for treatment of advanced/metastatic colorectal cancer.Network meta-analysis of the efficacy of first-line chemotherapy regimens in patients with advanced colorectal cancer.Phase II trial of gemcitabine plus UFT as salvage treatment in oxaliplatin, irinotecan and fluoropyrimidine-refractory metastatic colorectal cancer
P2860
Q26777704-CBFDC9BF-132C-403F-878F-E2B1AF401976Q28484668-4690B7D9-B7DD-4BA6-9734-5371F849FD4CQ36693127-3677E787-CF5E-40DC-88E0-FAE9B285C9AFQ37089932-D301F74D-A776-4BA5-B274-84F7CFACB526Q37102447-9CEF9FBE-7362-4DBF-BF84-C97139FD8DB8Q39246575-E6A2E10D-BF2C-4237-AB59-D888E90F3CC8Q40975248-DBD38953-2184-4A2A-B78A-D7225971E692Q41925374-1991074E-E120-42D3-9723-97A1775F7A89Q49805728-1A733955-CC36-40E5-BEBD-62BC430854A3Q57222417-A03E0869-E1C3-405E-8326-1910CE28AB0E
P2860
Multicenter, randomized phase II trial of bevacizumab plus folinic acid, fluorouracil, gemcitabine (FFG) versus bevacizumab plus folinic acid, fluorouracil, oxaliplatin (FOLFOX4) as first-line therapy for patients with advanced colorectal cancer.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh
2010年學術文章
@zh-hant
name
Multicenter, randomized phase ...... th advanced colorectal cancer.
@en
Multicenter, randomized phase ...... th advanced colorectal cancer.
@nl
type
label
Multicenter, randomized phase ...... th advanced colorectal cancer.
@en
Multicenter, randomized phase ...... th advanced colorectal cancer.
@nl
prefLabel
Multicenter, randomized phase ...... th advanced colorectal cancer.
@en
Multicenter, randomized phase ...... th advanced colorectal cancer.
@nl
P2093
P2860
P921
P1476
Multicenter, randomized phase ...... th advanced colorectal cancer.
@en
P2093
Cynthia G Leichman
David M Waterhouse
Donald J Higby
John F Gill
Luping Zhao
M Qaseem Khan
Patricia Hentschel
Paul S Ritch
Sandeep K Malik
Stefan Madajewicz
P2860
P2888
P304
P356
10.1007/S10637-010-9598-9
P577
2010-12-01T00:00:00Z
P6179
1031214040